



**ASX/Media Release**  
**31 August 2022**

### **Annual General Meeting**

**Emyria Limited (ASX: EMD) (Emyria or the Company)**, a data-backed drug development and care delivery company advises, in accordance with ASX Listing Rule 3.13.1, that it has scheduled the 2021 Annual General Meeting (AGM) of the Company to be held on 25 October 2022.

An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is Tuesday , 6 September 2022.

Nominations must be received at the Company's registered office no later than 5.00pm (Perth time) on Tuesday , 6 September 2022.

Release authorised by:  
Dr Michael Winlo, Managing Director

#### **For further information:**

Dr Michael Winlo  
Managing Director  
(08) 6559 2800  
[investors@emyria.com](mailto:investors@emyria.com)

Lexi O'Halloran  
Media/Investor Relations+ 61 (0) 404 577 076  
Lexi O'Halloran  
[lexi@janemorganmanagement.com.au](mailto:lexi@janemorganmanagement.com.au)

Andrew Williams Media Relations  
+61 (0) 412 614 125  
[andrew@profilemedia.com.au](mailto:andrew@profilemedia.com.au)

#### **About Emyria Limited**

Emyria Limited (ACN 625 085 734) is an Australian clinical drug development and care delivery company. **Emyria's Treatments** target large unmet needs and are focused on obtaining approval ("registration") with major global regulators. Emyria's treatment development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (Emerald Clinics - [www.emeraldclinics.com.au](http://www.emeraldclinics.com.au)).

**myriad data.**  
**individual care.**

Emyria Limited • ABN 96 625 085 734 • [info@emyria.com](mailto:info@emyria.com) •  
Talk 1300 436 363 • Suite 3, 43 Oxford Close, West Leederville •  
PO Box 1442, West Leederville, Western Australia 6901 • **emyria.com**



**Emyria Data** provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalized care programmes.

**Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.